Please login to the form below

Not currently logged in

Syndesi Therapeutics

This page shows the latest Syndesi Therapeutics news and features for those working in and with pharma, biotech and healthcare.

AbbVie acquires Syndesi Therapeutics in $1bn deal

AbbVie acquires Syndesi Therapeutics in $1bn deal

AbbVie has announced its acquisition of Syndesi Therapeutics, further expanding AbbVie’s neuroscience portfolio. ... The acquisition further reinforces AbbVie’s neurology pipeline, as four years ago, Syndesi Therapeutics gained the rights to UCB’s

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Subscribe to our email news alerts


Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Parkinson’s disease: past, present and future
Examining the history and complexities of Parkinson’s disease – one of the most prevalent neurodegenerative disorders that affects over 10 million people worldwide...
The 17th World Congress on Controversies in Neurology
This year, there was a focus on the rare disease neuromyelitis optica spectrum disorder that strikes suddenly and mainly impacts women...
Archetypes: Rethinking go-to-market expectations to drive commercial success
In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...